Remove Medicare Remove Outcomes Remove Technology
article thumbnail

New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol, and Weight Using Mobile Technology

DAIC

CVD is especially prevalent in the Medicare-aged population, affecting more than 75 percent of those aged 60-79 and more than 90 percent of those aged 80 and over. About the Study The study evaluated engagement and clinical outcomes among age 65+ participants of an mHealth app-based CV risk self-management program.

article thumbnail

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix Percutaneous Mechanical Circulatory Support Technology

DAIC

The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heart failure (ADHF) who are unresponsive to standard medical therapy. The company recently announced it has received CMS approval for Medicare coverage during the DRAIN-HF pivotal trial.

article thumbnail

Cleerly Raises $106 Million in Series C Extension Funding

DAIC

With this new funding, Cleerly will continue to scale its commercial growth and clinical evidence generation, helping health care professionals improve outcomes for patients across the coronary care pathway. We’re proud to be a part of Cleerly’s journey. This is what good software can do in the world!"

article thumbnail

Revolution Vibe CT System Now Available from GE Healthcare

DAIC

v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.

article thumbnail

Medtronic Presents New Data, Clinical Milestones at CRT 2025

DAIC

tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.

article thumbnail

CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

DAIC

milla1cf Tue, 04/23/2024 - 16:03 April 23, 2024 — CDL Nuclear Technologies , a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. CDL provides this service in compliance with all healthcare regulations. webflow.io

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , said Peter Altman , PhD., BioCardia’s President and Chief Executive Officer. “To

CMS 111